Ultomiris Market Report 2026

Ultomiris Market Overview

• The Ultomiris market growth in the historic period has been driven by improved diagnosis of rare autoimmune diseases, advancements in monoclonal antibody engineering • Market expansion is supported by increasing investments in rare disease drug development, rising adoption of subcutaneous formulations • Growth Driver: Impact Of Increasing Autoimmune Conditions On The Growth Of The Market • Market Trend: Drug Approval For Ultomiris In Neuromyelitis Optica Spectrum Disorder (NMOSD) • North America was the largest region in 2025.

What Is Covered Under Ultomiris Market?

Ultomiris is a prescription medication with the active ingredient ravulizumab-cwvz, a monoclonal antibody that inhibits a component of the immune system known as C5 in the complement cascade. It treats certain rare and severe autoimmune diseases by preventing the immune system from attacking healthy cells. The main types of clinical indications in ultomiris are paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder where red blood cells are destroyed prematurely, leading to hemolysis and blood clotting. It includes various formulations, such as intravenous solutions and subcutaneous formulations, and is distributed through hospitals and clinics and retail and specialty pharmacies. It caters to various end users, such as adult patients and pediatric patients.

What Is The Ultomiris Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in rare disease drug development, rising adoption of subcutaneous formulations, expansion of home-based infusion care, growing focus on long-term disease management, increasing demand for reduced treatment burden therapies. Major trends in the forecast period include increasing adoption of long-acting complement inhibitors, rising preference for extended dosing intervals, growing use of targeted autoimmune therapies, expansion of rare disease treatment programs, enhanced focus on patient-centric infusion models.

Global Ultomiris Market Segmentation

1) By Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD) 2) By Formulation: Intravenous Solution, Subcutaneous Formulation 3) By Distribution Channel: Hospital And Clinics, Retail And Specialty Pharmacies 4) By End User: Adult Patients, Pediatric Patients

What Are The Drivers Of The Ultomiris Market?

The increasing prevalence of autoimmune conditions is expected to propel the growth of the ultomiris market going forward. Autoimmune conditions refer to disorders in which the immune system mistakenly attacks and damages the body’s healthy cells and tissues. The increasing prevalence of autoimmune conditions can be attributed to both environmental factors, such as exposure to pollutants and chemicals, and improved diagnosis, which has led to more people being identified and treated for these diseases. Ultomiris treats autoimmune conditions such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement protein C5, reducing immune attacks on the body. For instance, in February 2024 according to the Arthritis Australia is a Australia-based non-profit organization In 2025, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA), with the numbers expected to rise by 2040 to approximately 280,040 males and 479,828 females. Therefore, the increasing prevalence of autoimmune conditions is driving the growth of the ultomiris industry. The rising healthcare expenditure is expected to propel the growth of the ultomiris market going forward. Healthcare expenditure refers to the financial resources spent on a country or region's medical services, infrastructure, insurance, and related activities. The rise in healthcare expenditure is due to the aging population and the increasing prevalence of chronic diseases, leading to higher ongoing medical management costs. Healthcare expenditure for ultomiris is used to cover the cost of the drug, its administration, patient monitoring, and continuing research and development to expand its therapeutic indications. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare expenditure in the USA rose by 5.6% in nominal terms from 2022 to 2023, marking a significant increase compared to the 0.9% growth observed in 2022. Therefore, rising healthcare expenditure is expected to propel the growth of the ultomiris industry.

Key Players In The Global Ultomiris Market

Major companies operating in the ultomiris market are AstraZeneca Plc.

Global Ultomiris Market Trends and Insights

The key trend in the ultomiris market is drug approval from regulatory authorities to expand its therapeutic indications and market reach. Drug approval is the process by which regulatory authorities evaluate and authorize a new drug for sale and use, ensuring its safety, efficacy, and quality based on clinical trial data. For instance, in March 2024, AstraZeneca, a UK-based pharmaceutical industry company, received the Food and Drug Administration (FDA) approval for ULTOMIRIS (ravulizumab-cwvz) for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) who are favorable for the anti-aquaporin-4 (AQP4) antibody. This approval is significant as ULTOMIRIS is the first long-acting C5 complement inhibitor for NMOSD, shown to reduce relapse risk by 98.6% in clinical trials. ULTOMIRIS helps prevent immune attacks on the central nervous system by inhibiting the complement system. However, it carries risks, including serious meningococcal infections and common side effects such as headache and urinary tract infections.

Regional Insights

North America was the largest region in the ultomiris market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Ultomiris Market?

The ultomiris market consists of sales of ultomiris injections, alpha-1 proteinase inhibitors, subcutaneous injections, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ultomiris Market Report 2026?

The ultomiris market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ultomiris industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.